tarlatamab   Click here for help

GtoPdb Ligand ID: 12969

Synonyms: AMG 757 | AMG-757 | AMG757 | Imdelltra® | tarlatamab-dlle
Approved drug
tarlatamab is an approved drug (FDA (2024))
Compound class: Antibody
Comment: Tarlatamab (AMG 757) is a bispecific T cell engager (BiTE®) type anti-Delta-like ligand 3 (DLL3) monoclonal antibody [5-6]. It co-engages DLL3 on cancer cells and CD3E on T cells to promote T cell-mediated tumour lysis. The rationale for investigating DLL3 as a cancer drug target is reviewed in [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Bioactivity Comments
The potency of tarlatamab-mediated lysis of HEK-293 cells expressing DLL3 is 2.2 pM in a T-cell dependent cellular cytotoxicity (TDCC) assay [5].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target
Sp.
Type
Action
Value
Parameter
Reference
CD3e Hs Antibody Binding 8.4 pKd - 5
⤷ pKd 8.4 (Kd 4.4x10-9 M) [5]
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target
Sp.
Type
Action
Value
Parameter
Reference
delta like canonical Notch ligand 3 Hs Antibody Binding 8.5 pKd - 5
⤷ pKd 8.5 (Kd 3x10-9 M) [5]